Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
European Urology(2018)
Abstract
Further to the positive outcome in the overall S-TRAC population, most subgroups defined by baseline characteristics demonstrated longer disease-free survival on sunitinib versus placebo, including patients with a higher risk of recurrence than the overall population, and patients with Fuhrman grade 3/4.
MoreTranslated text
Key words
Adjuvant,Disease-free survival,Renal cell carcinoma,Sunitinib
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined